Apconix
Nonclinical drug safety consultancy and ion channel screening lab for pharma and biotech drug developers
Highlights
- New on EvolcAdded 2026-10-31
About Apconix
ApconiX provides nonclinical toxicology and DMPK consultancy for drug discovery and development projects, including study outsourcing and monitoring. Its ion channel laboratory runs cardiac hERG and CiPA screening and offers the in-house iSLA seizure liability assay. It also offers Acuity target safety assessments and weight-of-evidence work that combines toxicology expertise with data science.
Customers are biotech, biopharma and academic organisations of any size, working on discovery and clinical development projects. Support is sold as flexible access to its scientists, from an hour or two of advice to multi-year support. The company works with international contract research organisations and states that 60% of its work is outside the UK.
The company was founded in 2014 and is headquartered in Alderley Edge, Cheshire, UK. It also has an office in Gothenburg, Sweden, opened in 2019. The website describes a team of over 100 scientists and reports a King's Award for Enterprise for Innovation in 2025.
Product: Nonclinical toxicology and DMPK consultancy, hERG/CiPA ion channel screening, iSLA seizure liability assay, and Acuity target safety assessments.
Jobs at Apconix
Leadership
- Michael Morton · Co-founder and Director - Ion Channel LabSource: company website
- Richard Knight · Co-founder and Director - Project ToxicologySource: company website
- Ruth Roberts · Co-founder and Director - Safety ScienceSource: company website
- Laurence Bishop · Head of Business Development & Deputy DirectorSource: company website
More biotech & pharma companies
Apis Assay Technologies
Molecular diagnostic assay kits and contract IVD development for diagnostics, biotech and pharma teamsNew on EvolcApollo Scientific
Supplies research chemicals, life-science reagents and synthesis services to laboratories, researchers and manufacturersNew on EvolcApollo Therapeutics
Portfolio biopharmaceutical company developing new medicines from university biomedical research and in-licensed clinical programsNew on EvolcApterna
Preclinical biotech developing liver-directed RNA therapies to restore liver function for patients with liver cancerNew on EvolcArecor
Develops therapeutics for people with diabetes, obesity and other cardiometabolic diseasesNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Google Tag Manager
- Google reCAPTCHA
- WordPress
- jQuery